Cargando…

A novel inflammatory biomarker, high-sensitivity C-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention

BACKGROUND: Patients with coronary artery disease (CAD) combined with diabetes have a higher risk of cardiovascular events, and high-sensitivity C-reactive protein (hs-CRP)-to-albumin ratio (CAR) is a novel inflammatory biomarker. However, whether the CAR can identify high-risk patients with CAD and...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jiawen, Zhu, Pei, Li, Yulong, Yan, Kailun, Tang, Xiaofang, Xu, Jingjing, Yang, Weixian, Qiao, Shubin, Yang, Yuejin, Gao, Runlin, Xu, Bo, Yuan, Jinqing, Zhao, Xueyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901126/
https://www.ncbi.nlm.nih.gov/pubmed/36747210
http://dx.doi.org/10.1186/s13098-022-00977-9
_version_ 1784882978272313344
author Li, Jiawen
Zhu, Pei
Li, Yulong
Yan, Kailun
Tang, Xiaofang
Xu, Jingjing
Yang, Weixian
Qiao, Shubin
Yang, Yuejin
Gao, Runlin
Xu, Bo
Yuan, Jinqing
Zhao, Xueyan
author_facet Li, Jiawen
Zhu, Pei
Li, Yulong
Yan, Kailun
Tang, Xiaofang
Xu, Jingjing
Yang, Weixian
Qiao, Shubin
Yang, Yuejin
Gao, Runlin
Xu, Bo
Yuan, Jinqing
Zhao, Xueyan
author_sort Li, Jiawen
collection PubMed
description BACKGROUND: Patients with coronary artery disease (CAD) combined with diabetes have a higher risk of cardiovascular events, and high-sensitivity C-reactive protein (hs-CRP)-to-albumin ratio (CAR) is a novel inflammatory biomarker. However, whether the CAR can identify high-risk patients with CAD and type 2 diabetes (T2DM) remains unclear. METHODS: The present study was based on a prospective and observational cohort with 10,724 individuals who undergo percutaneous coronary intervention (PCI) in Fu Wai Hospital throughout the year 2013 consecutively enrolled. The primary endpoint was all-cause mortality. The secondary endpoint was cardiac mortality. CAR was calculated with the formula: hs-CRP (mg/L)/albumin (g/L). According to the optimal cut-off value of CAR for all-cause mortality, patients were divided into higher CAR (CAR-H) and lower CAR (CAR-L) groups. RESULTS: A total of 2755 patients with T2DM who underwent PCI and received dual antiplatelet therapy were finally enrolled. During a follow-up of 5 years (interquartile range: 5.0–5.1 years), 126 (4.6%) all-cause mortalities and 74 (2.7%) cardiac mortalities were recorded. In the multivariable Cox model, CAR-H was associated with a higher risk of all-cause mortality (hazard ratio [HR]: 1.634, 95% confidence interval [CI] 1.121–2.380, p = 0.011) and cardiac mortality (HR: 1.733, 95% CI 1.059–2.835, p = 0.029) compared with CAR-L. When comparing the predictive value, CAR was superior to hs-CRP for all-cause mortality (area under the curve [AUC] 0.588 vs. 0.580, p = 0.002) and cardiac mortality (AUC 0.602 vs. 0.593, p = 0.004). CONCLUSION: In this real-world cohort study, a higher level of CAR was associated with worse 5-year outcomes among diabetic patients with PCI. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13098-022-00977-9.
format Online
Article
Text
id pubmed-9901126
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99011262023-02-07 A novel inflammatory biomarker, high-sensitivity C-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention Li, Jiawen Zhu, Pei Li, Yulong Yan, Kailun Tang, Xiaofang Xu, Jingjing Yang, Weixian Qiao, Shubin Yang, Yuejin Gao, Runlin Xu, Bo Yuan, Jinqing Zhao, Xueyan Diabetol Metab Syndr Research BACKGROUND: Patients with coronary artery disease (CAD) combined with diabetes have a higher risk of cardiovascular events, and high-sensitivity C-reactive protein (hs-CRP)-to-albumin ratio (CAR) is a novel inflammatory biomarker. However, whether the CAR can identify high-risk patients with CAD and type 2 diabetes (T2DM) remains unclear. METHODS: The present study was based on a prospective and observational cohort with 10,724 individuals who undergo percutaneous coronary intervention (PCI) in Fu Wai Hospital throughout the year 2013 consecutively enrolled. The primary endpoint was all-cause mortality. The secondary endpoint was cardiac mortality. CAR was calculated with the formula: hs-CRP (mg/L)/albumin (g/L). According to the optimal cut-off value of CAR for all-cause mortality, patients were divided into higher CAR (CAR-H) and lower CAR (CAR-L) groups. RESULTS: A total of 2755 patients with T2DM who underwent PCI and received dual antiplatelet therapy were finally enrolled. During a follow-up of 5 years (interquartile range: 5.0–5.1 years), 126 (4.6%) all-cause mortalities and 74 (2.7%) cardiac mortalities were recorded. In the multivariable Cox model, CAR-H was associated with a higher risk of all-cause mortality (hazard ratio [HR]: 1.634, 95% confidence interval [CI] 1.121–2.380, p = 0.011) and cardiac mortality (HR: 1.733, 95% CI 1.059–2.835, p = 0.029) compared with CAR-L. When comparing the predictive value, CAR was superior to hs-CRP for all-cause mortality (area under the curve [AUC] 0.588 vs. 0.580, p = 0.002) and cardiac mortality (AUC 0.602 vs. 0.593, p = 0.004). CONCLUSION: In this real-world cohort study, a higher level of CAR was associated with worse 5-year outcomes among diabetic patients with PCI. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13098-022-00977-9. BioMed Central 2023-02-06 /pmc/articles/PMC9901126/ /pubmed/36747210 http://dx.doi.org/10.1186/s13098-022-00977-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Li, Jiawen
Zhu, Pei
Li, Yulong
Yan, Kailun
Tang, Xiaofang
Xu, Jingjing
Yang, Weixian
Qiao, Shubin
Yang, Yuejin
Gao, Runlin
Xu, Bo
Yuan, Jinqing
Zhao, Xueyan
A novel inflammatory biomarker, high-sensitivity C-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention
title A novel inflammatory biomarker, high-sensitivity C-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention
title_full A novel inflammatory biomarker, high-sensitivity C-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention
title_fullStr A novel inflammatory biomarker, high-sensitivity C-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention
title_full_unstemmed A novel inflammatory biomarker, high-sensitivity C-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention
title_short A novel inflammatory biomarker, high-sensitivity C-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention
title_sort novel inflammatory biomarker, high-sensitivity c-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901126/
https://www.ncbi.nlm.nih.gov/pubmed/36747210
http://dx.doi.org/10.1186/s13098-022-00977-9
work_keys_str_mv AT lijiawen anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT zhupei anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT liyulong anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT yankailun anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT tangxiaofang anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT xujingjing anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT yangweixian anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT qiaoshubin anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT yangyuejin anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT gaorunlin anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT xubo anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT yuanjinqing anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT zhaoxueyan anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT lijiawen novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT zhupei novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT liyulong novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT yankailun novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT tangxiaofang novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT xujingjing novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT yangweixian novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT qiaoshubin novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT yangyuejin novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT gaorunlin novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT xubo novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT yuanjinqing novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention
AT zhaoxueyan novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention